Last edition
News about "The New England Journal of Medicine"
US FDA Approves ETCAMAH Plus CDK4/6 Inhibitor for Advanced HR-Positive Breast Cancer
US approves ETCAMAH (camizestrant) plus a CDK4/6 inhibitor for first-line advanced HR-positive breast cancer, reducing progression or death risk by 56 percent.
The New England Journal Of Medicine | 05/09/2026 | By News Bureau
The European Union (EU) has approved Enhertu plus pertuzumab as a new first-line regimen for HER2-positive metastatic breast cancer, reducing progression or death risk by 44 percent.
The New England Journal Of Medicine | 02/09/2026 | By News Bureau
EU Approves Imfinzi as First Perioperative Immunotherapy for Gastric and Gastroesophageal Cancers
The EU approval of Imfinzi is based on phase-III MATTERHORN trial results, which showed significant improvements in event-free and overall survival in early-stage gastric and gastroesophageal cancer patients.
The New England Journal Of Medicine | 17/03/2026 | By Akanki | 167
Enhertu Secures US BTD Status in Early HER2-Positive Breast Cancer
The US FDA has granted Breakthrough Therapy Designation to Enhertu for use as post-neoadjuvant treatment in patients with HER2-positive early breast cancer, marking the tenth such designation for AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate, supported by phase III DESTINY-Breast05 trial results.
The New England Journal Of Medicine | 23/12/2025 | By News Bureau | 196
Orforglipron by Lily Shows Significant Weight Loss and Cardiometabolic Gains in ATTAIN-1 Results
Orforglipron by Eli Lily demonstrated significant improvements across key cardiometabolic risk factors, supporting its potential as a treatment option for millions living with obesity.
The New England Journal Of Medicine | 18/09/2025 | By Dineshwori | 590
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy